| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer (NCT05244434) | City of Hope Medical Center | 2022-07-03 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (NCT05098210) | Fred Hutchinson Cancer Center | 2022-06-09 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (NCT05319873) | Jonsson Comprehensive Cancer Center | 2022-04-07 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer (NCT05215769) | Ohio State University Comprehensive Cancer Center | 2022-03-30 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer (NCT05177796) | M.D. Anderson Cancer Center | 2022-03-11 |
| Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer (NCT06206239) | Thomas Jefferson University | 2022-03-09 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (NCT05081492) | City of Hope Medical Center | 2021-10-18 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel (NCT04862585) | Ohio State University Comprehensive Cancer Center | 2021-10-07 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942) | National Cancer Institute (NCI) | 2021-08-25 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (NCT04639245) | Fred Hutchinson Cancer Center | 2021-07-19 |
| Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer (NCT04750473) | Emory University | 2021-07-16 |
| Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases (NCT04647916) | SWOG Cancer Research Network | 2021-06-08 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (NCT04108858) | National Cancer Institute (NCI) | 2021-05-20 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (NCT03606967) | National Cancer Institute (NCI) | 2021-04-13 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer (NCT04190056) | University of California, San Francisco | 2021-03-11 |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial (NCT04756505) | M.D. Anderson Cancer Center | 2021-03-07 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913) | National Cancer Institute (NCI) | 2021-03-01 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (NCT04418219) | Thomas Jefferson University | 2020-12-21 |
| Nipple Aspirate Fluid in Detecting Breast Cancer (NCT03715959) | Ohio State University Comprehensive Cancer Center | 2020-12-10 |
| Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring (NCT04906369) | Mayo Clinic | 2020-11-16 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (NCT04351230) | Academic and Community Cancer Research United | 2020-11-11 |
| Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer (NCT04205071) | Ohio State University Comprehensive Cancer Center | 2020-11-01 |
| Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study (NCT04316117) | ECOG-ACRIN Cancer Research Group | 2020-09-15 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (NCT04090398) | National Cancer Institute (NCI) | 2020-08-04 |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer (NCT04517838) | Mayo Clinic | 2020-07-31 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (NCT04090567) | M.D. Anderson Cancer Center | 2020-07-28 |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (NCT04445844) | Mridula George, MD | 2020-07-13 |
| Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors (NCT04526587) | Roswell Park Cancer Institute | 2020-07-03 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897) | National Cancer Institute (NCI) | 2020-06-17 |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer (NCT04120246) | Veana Therapeutics | 2020-04-08 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. (NCT04305834) | City of Hope Medical Center | 2020-03-25 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (NCT03554044) | University of California, San Francisco | 2020-02-05 |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT04249167) | Mayo Clinic | 2020-01-23 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer (NCT03737695) | Mayo Clinic | 2019-09-16 |
| Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (NCT03941730) | Mayo Clinic | 2019-08-28 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer (NCT03207529) | M.D. Anderson Cancer Center | 2019-06-07 |
| Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (NCT04256941) | M.D. Anderson Cancer Center | 2019-05-31 |
| Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer (NCT03853707) | City of Hope Medical Center | 2019-03-04 |
| Intravital Microscopy in Human Solid Tumors (NCT03823144) | Mayo Clinic | 2019-02-28 |
| A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer (NCT03803761) | National Cancer Institute (NCI) | 2019-02-13 |
| Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (NCT03691493) | Emory University | 2019-02-08 |
| Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice (NCT04297384) | Roswell Park Cancer Institute | 2019-02-06 |
| AMTEC IIT: Phase 2 Multiarm Study in TNBC (NCT03801369) | Gordon Mills, MD, PhD | 2018-12-12 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (NCT03723928) | SWOG Cancer Research Network | 2018-09-17 |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (NCT03774472) | M.D. Anderson Cancer Center | 2018-08-20 |
| M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (NCT03579472) | M.D. Anderson Cancer Center | 2018-05-30 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer (NCT03544125) | OHSU Knight Cancer Institute | 2018-05-03 |
| Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03524170) | M.D. Anderson Cancer Center | 2018-04-30 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (NCT03179904) | Mayo Clinic | 2017-08-03 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer (NCT03106077) | M.D. Anderson Cancer Center | 2017-06-05 |
| Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer (NCT02849496) | National Cancer Institute (NCI) | 2017-03-30 |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT02453620) | National Cancer Institute (NCI) | 2016-02-12 |
| Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival (NCT02364557) | NRG Oncology | 2014-12-24 |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282) | National Cancer Institute (NCI) | 2014-03-29 |
| Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer (NCT01334021) | M.D. Anderson Cancer Center | 2011-05-31 |
| Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer (NCT01149083) | National Cancer Institute (NCI) | 2010-06-30 |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (NCT00338728) | M.D. Anderson Cancer Center | 2003-10-03 |